Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy.
Journal
Nature
ISSN: 1476-4687
Titre abrégé: Nature
Pays: England
ID NLM: 0410462
Informations de publication
Date de publication:
08 Apr 2024
08 Apr 2024
Historique:
received:
28
06
2023
accepted:
16
02
2024
medline:
9
4
2024
pubmed:
9
4
2024
entrez:
8
4
2024
Statut:
aheadofprint
Résumé
RAS oncogenes (collectively NRAS, HRAS and especially KRAS) are among the most frequently mutated genes in cancer, with common driver mutations occurring at codons 12, 13 and 61
Identifiants
pubmed: 38589574
doi: 10.1038/s41586-024-07205-6
pii: 10.1038/s41586-024-07205-6
doi:
Banques de données
ClinicalTrials.gov
['NCT05379985']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Simanshu, D. K., Nissley, D. V. & McCormick, F. RAS proteins and their regulators in human disease. Cell 170, 17–33 (2017).
pubmed: 28666118
pmcid: 5555610
doi: 10.1016/j.cell.2017.06.009
Cox, A. D., Fesik, S. W., Kimmelman, A. C., Luo, J. & Der, C. J. Drugging the undruggable RAS: mission possible? Nat. Rev. Drug Discov. 13, 828–851 (2014).
pubmed: 25323927
pmcid: 4355017
doi: 10.1038/nrd4389
Moore, A. R., Rosenberg, S. C., McCormick, F. & Malek, S. RAS-targeted therapies: is the undruggable drugged? Nat. Rev. Drug. Discov. 19, 533–552 (2020).
pubmed: 32528145
pmcid: 7809886
doi: 10.1038/s41573-020-0068-6
Lee, J. K. et al. Comprehensive pan-cancer genomic landscape of KRAS altered cancers and real-world outcomes in solid tumors. npj Precis. Oncol. 6, 91 (2022).
Malumbres, M. & Barbacid, M. RAS oncogenes: the first 30 years. Nat. Rev. Cancer 3, 459–465 (2003).
pubmed: 12778136
doi: 10.1038/nrc1097
Siegel, R. L., Wagle, N. S., Cercek, A., Smith, R. A. & Jemal, A. Colorectal cancer statistics, 2023. CA Cancer J. Clin. 73, 233–254 (2023).
pubmed: 36856579
doi: 10.3322/caac.21772
Pylayeva-Gupta, Y., Grabocka, E. & Bar-Sagi, D. RAS oncogenes: weaving a tumorigenic web. Nat. Rev. Cancer 11, 761–774 (2011).
pubmed: 21993244
pmcid: 3632399
doi: 10.1038/nrc3106
Johnson, C., Burkhart, D. L. & Haigis, K. M. Classification of KRAS-activating mutations and the implications for therapeutic intervention. Cancer Discov. 12, 913–923 (2022).
pubmed: 35373279
pmcid: 8988514
doi: 10.1158/2159-8290.CD-22-0035
Papke, B. & Der, C. J. Drugging RAS: know the enemy. Science 355, 1158–1163 (2017).
pubmed: 28302824
doi: 10.1126/science.aam7622
Janne, P. A. et al. Adagrasib in non-small-cell lung cancer harboring a KRAS(G12C) mutation. N. Engl. J. Med. 387, 120–131 (2022).
pubmed: 35658005
doi: 10.1056/NEJMoa2204619
Skoulidis, F. et al. Sotorasib for lung cancers with KRAS p.G12C mutation. N. Engl. J. Med. 384, 2371–2381 (2021).
pubmed: 34096690
pmcid: 9116274
doi: 10.1056/NEJMoa2103695
Schulze, C. J. et al. Chemical remodeling of a cellular chaperone to target the active state of mutant KRAS. Science 381, 794–799 (2023).
pubmed: 37590355
pmcid: 10474815
doi: 10.1126/science.adg9652
Sanglier, J. J. et al. Sanglifehrins A, B, C and D, novel cyclophilin-binding compounds isolated from Streptomyces sp. A92-308110. I. Taxonomy, fermentation, isolation and biological activity. J. Antibiot. 52, 466–473 (1999).
doi: 10.7164/antibiotics.52.466
Zhang, Z. & Shokat, K. M. Bifunctional small-molecule ligands of K-ras Induce Its association with immunophilin proteins. Angew. Chem. Int. Ed. Engl. 58, 16314–16319 (2019).
pubmed: 31557383
pmcid: 6980260
doi: 10.1002/anie.201910124
Guo, Z. et al. Rapamycin-inspired macrocycles with new target specificity. Nat. Chem. 11, 254–263 (2019).
pubmed: 30532015
doi: 10.1038/s41557-018-0187-4
Shigdel, U. K. et al. Genomic discovery of an evolutionarily programmed modality for small-molecule targeting of an intractable protein surface. Proc. Natl Acad. Sci. USA 117, 17195–17203 (2020).
pubmed: 32606248
pmcid: 7382241
doi: 10.1073/pnas.2006560117
Mackman, R. L. et al. Discovery of a potent and orally bioavailable cyclophilin inhibitor derived from the sanglifehrin macrocycle. J. Med. Chem. 61, 9473–9499 (2018).
pubmed: 30074795
doi: 10.1021/acs.jmedchem.8b00802
Drosten, M. et al. Genetic analysis of Ras signalling pathways in cell proliferation, migration and survival. EMBO J. 29, 1091–1104 (2010).
pubmed: 20150892
pmcid: 2845279
doi: 10.1038/emboj.2010.7
Ihle, N. T. et al. Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. J. Natl Cancer Inst. 104, 228–239 (2012).
pubmed: 22247021
pmcid: 3274509
doi: 10.1093/jnci/djr523
Hobbs, G. A. et al. Atypical KRAS(G12R) mutant is impaired in PI3K signaling and macropinocytosis in pancreatic cancer. Cancer Discov. 10, 104–123 (2020).
pubmed: 31649109
doi: 10.1158/2159-8290.CD-19-1006
Cook, J. H., Melloni, G. E. M., Gulhan, D. C., Park, P. J. & Haigis, K. M. The origins and genetic interactions of KRAS mutations are allele- and tissue-specific. Nat. Commun. 12, 1808 (2021).
pubmed: 33753749
pmcid: 7985210
doi: 10.1038/s41467-021-22125-z
Poulin, E. J. et al. Tissue-specific oncogenic activity of KRAS(A146T). Cancer Discov. 9, 738–755 (2019).
pubmed: 30952657
pmcid: 6548671
doi: 10.1158/2159-8290.CD-18-1220
Negrao, M. V. et al. Comutations and KRASG12C inhibitor efficacy in advanced NSCLC. Cancer Discov. 13, 1556–1571 (2023).
pubmed: 37068173
doi: 10.1158/2159-8290.CD-22-1420
Rabara, D. et al. KRAS G13D sensitivity to neurofibromin-mediated GTP hydrolysis. Proc. Natl Acad. Sci. USA 116, 22122–22131 (2019).
pubmed: 31611389
pmcid: 6825300
doi: 10.1073/pnas.1908353116
Hymowitz, S. G. & Malek, S. Targeting the MAPK pathway in RAS mutant cancers. Cold Spring Harb. Perspect. Med. 8, a031492 (2018).
pubmed: 29440321
pmcid: 6211377
doi: 10.1101/cshperspect.a031492
Collisson, E. A. et al. A central role for RAF→MEK→ERK signaling in the genesis of pancreatic ductal adenocarcinoma. Cancer Discov. 2, 685–693 (2012).
pubmed: 22628411
pmcid: 3425446
doi: 10.1158/2159-8290.CD-11-0347
Morris, E. J. et al. Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors. Cancer Discov. 3, 742–750 (2013).
pubmed: 23614898
doi: 10.1158/2159-8290.CD-13-0070
Peng, S. B. et al. Inhibition of RAF isoforms and active dimers by LY3009120 leads to anti-tumor activities in RAS or BRAF mutant cancers. Cancer Cell 28, 384–398 (2015).
pubmed: 26343583
doi: 10.1016/j.ccell.2015.08.002
Daud, A. & Tsai, K. Management of treatment-related adverse events with agents targeting the MAPK pathway in patients with metastatic melanoma. Oncologist 22, 823–833 (2017).
pubmed: 28526719
pmcid: 5507648
doi: 10.1634/theoncologist.2016-0456
Flaherty, K. T. et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N. Engl. J. Med. 367, 107–114 (2012).
pubmed: 22663011
doi: 10.1056/NEJMoa1203421
Wu, J. et al. Characterization and management of ERK inhibitor associated dermatologic adverse events: analysis from a nonrandomized trial of ulixertinib for advanced cancers. Invest. New Drugs 39, 785–795 (2021).
pubmed: 33389388
pmcid: 9282166
doi: 10.1007/s10637-020-01035-9
Wasko, U. N. et al. Tumor-selective effects of active RAS inhibition in pancreatic ductal adenocarcinoma. Preprint at bioRxiv https://www.biorxiv.org/content/10.1101/2023.12.03.569791v1 (2023).
Hakim, S., Craig, J. M., Koblinski, J. E. & Clevenger, C. V. Inhibition of the activity of cyclophilin A impedes prolactin receptor-mediated signaling, mammary tumorigenesis, and metastases. iScience 23, 101581 (2020).
pubmed: 33083747
pmcid: 7549119
doi: 10.1016/j.isci.2020.101581
Li, Y. & Yang, L. Cyclophilin A represses reactive oxygen species generation and death of hypoxic non-small-cell lung cancer cells by degrading thioredoxin-interacting protein. Cell Cycle 21, 1996–2007 (2022).
pubmed: 35579671
pmcid: 9415537
doi: 10.1080/15384101.2022.2078615
Wang, S., Li, M., Xing, L. & Yu, J. High expression level of peptidylprolyl isomerase A is correlated with poor prognosis of liver hepatocellular carcinoma. Oncol. Lett. 18, 4691–4702 (2019).
pubmed: 31611978
pmcid: 6781733
Awad, M. M. et al. Acquired resistance to KRAS(G12C) inhibition in cancer. N. Engl. J. Med. 384, 2382–2393 (2021).
pubmed: 34161704
pmcid: 8864540
doi: 10.1056/NEJMoa2105281
Zhao, Y. et al. Diverse alterations associated with resistance to KRAS(G12C) inhibition. Nature 599, 679–683 (2021).
pubmed: 34759319
pmcid: 8887821
doi: 10.1038/s41586-021-04065-2
Ho, C. S. L. et al. HER2 mediates clinical resistance to the KRAS(G12C) inhibitor sotorasib, which is overcome by co-targeting SHP2. Eur. J. Cancer 159, 16–23 (2021).
pubmed: 34715459
doi: 10.1016/j.ejca.2021.10.003
Ryan, M. B. et al. Vertical pathway inhibition overcomes adaptive feedback resistance to KRAS(G12C) inhibition. Clin. Cancer Res. 26, 1633–1643 (2020).
pubmed: 31776128
doi: 10.1158/1078-0432.CCR-19-3523
Kwan, A. K., Piazza, G. A., Keeton, A. B. & Leite, C. A. The path to the clinic: a comprehensive review on direct KRAS(G12C) inhibitors. J. Exp. Clin. Cancer Res. 41, 27 (2022).
pubmed: 35045886
pmcid: 8767686
doi: 10.1186/s13046-021-02225-w
Ostrem, J. M. & Shokat, K. M. Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design. Nat. Rev. Drug Discov. 15, 771–785 (2016).
pubmed: 27469033
doi: 10.1038/nrd.2016.139
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A. & Shokat, K. M. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature 503, 548–551 (2013).
pubmed: 24256730
pmcid: 4274051
doi: 10.1038/nature12796
Corsello, S. M. et al. Discovering the anti-cancer potential of non-oncology drugs by systematic viability profiling. Nat. Cancer 1, 235–248 (2020).
pubmed: 32613204
pmcid: 7328899
doi: 10.1038/s43018-019-0018-6